SeekingAlpha · Sep 9, 2026
Tenax Therapeutics, Inc. (TENX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow
2026-09-09. The following slide deck was published by Tenax Therapeutics, Inc.
TE
NASDAQ · TENX
Tenax Therapeutics, Inc.
Healthcare · Biotechnology
$1.86
Up+$0.05 (+2.73%)
Updated Sep 18, 2026, 2:54 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 45.01M
- P/E ratio
- -12.4
- Dividend yield
- 0.00%
- 52-week range
- $1.31 – $19.40
- Volume
- 3.57M
- Avg. volume
- 113.76K
Price performance
TENX price history
1M range · 0 trading sessions · Daily adjusted prices
TENX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest TENX news
The latest Smart Investors Daily articles mentioning TENX.
Stock researchCompany · Overview
TENX research
Overview
Company profile and research snapshot.
Company profile
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 31, 2026 | Guggenheim | Neutral | — |
| Aug 11, 2026 | Canaccord Genuity | Buy | — |
| Aug 11, 2026 | Chardan Capital | Neutral | — |
| Aug 11, 2026 | Guggenheim | Buy | — |
| Aug 11, 2026 | Evercore ISI Group | In-Line | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 4, 2026
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?
Tenax Therapeutics, Inc. (NASDAQ:TENX) has a possible route forward for TNX-103, but the Phase 3 LEVEL trial did not establish efficacy in the overall population. The study evaluated oral levosimendan in 241 patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF. At Week 12, the adjusted improvement in six-minute walk […]
Yahoo · Sep 1, 2026
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET. The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage. About Tenax TherapeuticsTenax Therapeutics, Inc. is a P
Benzinga · Sep 1, 2026
5 Stocks In The Spotlight From Wall Street's Most Accurate Analysts Last Month
U.S. stocks settled lower on Monday, with the Dow Jones index falling more than 350 points during the session. Renewed US-Iran strikes over the weekend sent crude sharply higher Monday, reviving inflation fears and
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
